Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
The EIR was issued following an inspection of the facility from September 8 to September 16, 2025
This is also an important milestone in our product strategy for our expansion into the larger Latin American market
The innovation -- UPM Circular Renewable Black -- is the world’s first bio-based, near-infrared (NIR) detectable, carbon-negative black
The product will be marketed by Dr. Reddy's Laboratories Inc.
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
Siponimod Tablets is indicated for the treatment of relapsing forms of multiple sclerosis
This inspection was conducted following the warning letter issued by the USFDA
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Subscribe To Our Newsletter & Stay Updated
